{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:21:41Z","timestamp":1792844501683,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN263201200001C"],"award-info":[{"award-number":["HHSN263201200001C"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ophtha.2024.05.024","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T08:06:11Z","timestamp":1717661171000},"page":"1324-1332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Oral Hypoxia-Inducible Factor 2\u03b1 Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease"],"prefix":"10.1016","volume":"131","author":[{"given":"Henry E.","family":"Wiley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaprasad","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-9468","authenticated-orcid":false,"given":"Jodi K.","family":"Maranchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9529-4870","authenticated-orcid":false,"given":"Ane Bundsb\u00e6k B\u00f8ndergaard","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-2806","authenticated-orcid":false,"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan S.","family":"Gombos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2262-0011","authenticated-orcid":false,"given":"Tobias","family":"Else","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0010-8551","authenticated-orcid":false,"given":"Benjamin L.","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elizabeth","family":"Hartnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna R.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo F.","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-3109","authenticated-orcid":false,"given":"W. Marston","family":"Linehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-9802","authenticated-orcid":false,"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa T.","family":"Thavikulwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiarnan D.L.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bellur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Mac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Cukras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2024.05.024_bib1","series-title":"Hemangioblastoma of the retina and von Hippel-Lindau disease. Ryan\u2019s Retina","first-page":"2427","author":"Wiley","year":"2018"},{"issue":"1","key":"10.1016\/j.ophtha.2024.05.024_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ophtha.2007.03.009","article-title":"Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ophtha.2024.05.024_bib3","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1097\/IAE.0000000000002572","article-title":"Management of retinal hemangioblastoma in von Hippel-Lindau disease","volume":"39","author":"Wiley","year":"2019","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ophtha.2024.05.024_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumour suppressor gene","volume":"15","author":"Gossage","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"10.1016\/j.ophtha.2024.05.024_bib5","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"13","key":"10.1016\/j.ophtha.2024.05.024_bib6","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","article-title":"Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma","volume":"25","author":"Raval","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.ophtha.2024.05.024_bib7","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-05-2519","article-title":"Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway","volume":"66","author":"Carroll","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ophtha.2024.05.024_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","article-title":"Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein","volume":"1","author":"Kondo","year":"2002","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.ophtha.2024.05.024_bib9","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ophtha.2024.05.024_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"7627","key":"10.1016\/j.ophtha.2024.05.024_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"7627","key":"10.1016\/j.ophtha.2024.05.024_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.ophtha.2024.05.024_bib13","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","article-title":"A\u00a0small-molecule antagonist of HIF2alpha is efficacious in preclinical models of renal cell carcinoma","volume":"76","author":"Wallace","year":"2016","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ophtha.2024.05.024_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","article-title":"HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron","volume":"1","author":"Mandriota","year":"2002","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.ophtha.2024.05.024_bib15","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1210\/jc.2006-0920","article-title":"Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations","volume":"91","author":"Pollard","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ophtha.2024.05.024_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0002-9440(10)65541-1","article-title":"Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF\/HIF-2alpha","volume":"153","author":"Flamme","year":"1998","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.ophtha.2024.05.024_bib17","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-11-2759","article-title":"Molecular profiling of pancreatic neuroendocrine tumors in sporadic and von Hippel-Lindau patients","volume":"18","author":"Speisky","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ophtha.2024.05.024_bib18","first-page":"75","article-title":"Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma","volume":"102","author":"Chan","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"21","key":"10.1016\/j.ophtha.2024.05.024_bib19","first-page":"7051","article-title":"Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease","volume":"63","author":"Vortmeyer","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ophtha.2024.05.024_bib20","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1371\/journal.pmed.0040060","article-title":"von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells","volume":"4","author":"Park","year":"2007","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.ophtha.2024.05.024_bib21","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1158\/0008-5472.CAN-05-3505","article-title":"Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell","volume":"66","author":"Glasker","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ophtha.2024.05.024_bib22","first-page":"697","article-title":"Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease","volume":"11","author":"Chan","year":"2005","journal-title":"Mol Vis"},{"issue":"5","key":"10.1016\/j.ophtha.2024.05.024_bib23","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/0008-5472.CAN-17-1718","article-title":"Deletion of the von Hippel-Lindau gene in hemangioblasts causes hemangioblastoma-like lesions in murine retina","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.ophtha.2024.05.024_bib24","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ophtha.2024.05.024_bib25","doi-asserted-by":"crossref","first-page":"S808","DOI":"10.1016\/j.annonc.2022.08.074","article-title":"LBA69\u2014belzutifan, a HIF-2\u03b1 inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study","volume":"33","author":"Srinivasan","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ophtha.2024.05.024_bib26","series-title":"Welireg (belzutifan): U.S. prescribing information","year":"2023"},{"issue":"2","key":"10.1016\/j.ophtha.2024.05.024_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/IAE.0b013e318030a290","article-title":"Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina","volume":"27","author":"Dahr","year":"2007","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.ophtha.2024.05.024_bib28","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.ophtha.2008.04.033","article-title":"Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2024.05.024_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.oret.2016.10.007","article-title":"Systemic sunitinib malate treatment for advanced juxtapapillary retinal hemangioblastomas associated with von Hippel-Lindau disease","volume":"1","author":"Knickelbein","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2024.05.024_bib30","first-page":"2782","article-title":"Ocular findings in a phase 2 trial testing the first-in-class oral HIF-2\u03b1 inhibitor, PT2385, for renal cell carcinoma in von Hippel-Lindau disease","volume":"60","author":"Wiley","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2024.05.024_bib31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.annonc.2023.10.090","article-title":"LBA88\u2014belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase III LITESPARK-005 study; Madrid, Spain","volume":"34","author":"Albiges","year":"2023","journal-title":"Annals Oncology"},{"issue":"suppl_2","key":"10.1016\/j.ophtha.2024.05.024_bib32","first-page":"S1013","article-title":"18810\u2014safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: results of the randomized phase II LITESPARK-013 study","volume":"34","author":"Agarwal","year":"2023","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ophtha.2024.12.032","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000}}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024003191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024003191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:37:54Z","timestamp":1764121074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024003191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0161642024003191"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.05.024","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Hypoxia-Inducible Factor 2\u03b1 Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}